Clinical trials: GastroEsophageal Cancer
Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer
Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
The objective of this study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of BL-M17D1 in patients with HER2-Expressing or HER2-Mutant Advanced or Metastatic Solid Tumors.
- Conditions
- Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer, Unresectable Breast Carcinoma, Her2-Positive
- Trial name
- NCT06714617
- Testing
- BL-M17D1
- Where
- 9 sites in United States
- Volunteers
- 3 people
- Sponsor
- SystImmune Inc.
Lymphoma, Advanced Solid Tumors
Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101
This is an open label, multicenter, phase 1/1b study to assess safety/tolerability and preliminary clinical activity of E7766 as a single agent administered intratumorally in participants with advanced solid tumors or lymphomas.
- Trial name
- NCT04144140
- Testing
- E7766
- Where
- 13 sites in United States, France and 3 more
- Volunteers
- 24 people
- Sponsor
- Eisai Inc.
Ovarian Carcinoma, Fallopian Tube Carcinoma
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
This is a first-in-human, open-label, multi-center, Phase 1, dose-escalation study with expansion cohorts to evaluate NM32-2668 for safety and immunogenicity, to determine the maximal tolerated dose and recommended Phase 2 dose…
- Conditions
- Ovarian Carcinoma, Fallopian Tube Carcinoma, Peritoneal Carcinoma, Endometrial Cancer
- Trial name
- NCT06299163
- Testing
- NM32-2668
- Where
- 11 sites in United States
- Volunteers
- 11 people
- Sponsor
- Numab Therapeutics AG
Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
This study investigates treatment of cadonilimab or placebo combined with SOX chemotherapy (oxaliplatin + tegafur-gimeracil-oteracil potassium) given before surgery (neoadjuvant) and cadonilimab or placebo combined with SOX…
- Trial name
- NCT07023315
- Testing
- Cadonilimab, SOX chemotherapy
- Where
- 6 sites in China
- Volunteers
- 760 people
- Sponsor
- Akeso
Gastrointestinal Neoplasms, Esophagogastric Junction
Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer
This is a Global Study of Neoadjuvant-Adjuvant Durvalumab or Placebo and FLOT Chemotherapy Followed by Adjuvant Durvalumab or Placebo in Patients with Resectable Gastric and Gastroesophageal Cancer (GC/GEJC) (MATTERHORN).
- Trial name
- NCT04592913
- Testing
- Durvalumab, FLOT chemotherapy
- Where
- 156 sites in United States, Argentina and 18 more
- Volunteers
- 957 people
- Sponsor
- AstraZeneca
HER2-expressing Cancers
A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers
This is a first-in-human, Phase 1, multicenter, open-label, dose-escalation study to establish the maximum-tolerated dose (MTD) or recommended dosage (RD) of ZW49, the investigational agent under study, and to assess the safety…
- Trial name
- NCT03821233
- Testing
- ZW49
- Where
- 16 sites in United States, Australia and 2 more
- Volunteers
- 112 people
- Sponsor
- Zymeworks BC Inc.
Gastric Cancer Adenocarcinoma Metastatic, Gastroesophageal Adenocarcinoma
A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer
A first-in-human study using BDC-4182 as a single agent in gastric and gastroesophageal cancers
- Trial name
- NCT06921837
- Testing
- BDC-4182
- Where
- 16 sites in Australia, South Korea and 1 more
- Volunteers
- 122 people
- Sponsor
- Bolt Biotherapeutics, Inc.
Solid Tumor, Colorectal Cancer
Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors
This is a first-in-human Phase 1a/1b, multicenter, open-label, dose-escalation, dose and schedule optimization, and expansion study of TPST-1495 as a single agent and in combination with pembrolizumab to determine its maximum…
- Conditions
- Solid Tumor, Colorectal Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT04344795
- Testing
- TPST-1495 twice daily, TPST-1495 once daily or on intermittent schedule, Pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 89 people
- Sponsor
- Tempest Therapeutics
Gastric/Gastroesophageal Junction Cancer
KN026 in Patients With HER2 Expressing Gastric/Gastroesophageal Junction Cancer
This is an open-label, phase 2 study of KN026 in subjects with HER2 expressing gastric/gastroesophageal junction cancer to evaluate efficacy and safety.
- Trial name
- NCT03925974
- Testing
- KN026 10 mg/kg QW, KN026 20 mg/kg Q2W, KN026 30 mg/kg Q3W
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Gastric Adenocarcinoma, Pancreatic Cancer
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
An open, multicenter, phase Ib/II study to evaluate the efficacy, safety and pharmacokinetics of CT041 autologous CAR T-cell injection in patients with advanced gastric/ gastroesophageal junction adenocarcinoma and pancreatic…
- Conditions
- Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT04581473
- Testing
- CT041 autologous CAR T-cell injection, Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）
- Where
- 24 sites in China
- Volunteers
- 192 people
- Sponsor
- CARsgen Therapeutics Co., Ltd.
Adenocarcinoma, Gastric, Neoplasm, Breast
DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein
HER2-positive cancer is a cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2). HER2 promotes the growth of certain cancer cells.
- Trial name
- NCT03368196
- Testing
- DS-8201a
- Where
- 2 sites in Taiwan
- Volunteers
- 12 people
- Sponsor
- Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company
Advanced Gastric Cancer, Gastroesophageal Cancer
Study on the Safety and Effectiveness of UCB-NK Cell Infusion in the Treatment of Advanced Gastric Cancer and Gastroesophageal Cancer
This study is an open, single infusion, cell infusion dose /method exploration study. In patients with gastric cancer and gastroesophageal cancer without effective treatment, the safety of UCB-NK cell immunotherapy was evaluated…
- Trial name
- NCT04385641
- Testing
- Cell infusion for Dose-finding (Group A), Cell infusion for Extended research (Group B)
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Shandong Golden Brick Biotechnology Co., Ltd.
Mitral Regurgitation
Transcatheter Mitral Valve Replacement in Patients With Severe Symptomatic Mitral Regurgitation - APOLLO-EU Trial
Evaluate the safety and efficacy of Medtronic Intrepid™ TMVR TF System in patients with moderate-to-severe or severe symptomatic mitral regurgitation, or moderate symptomatic mitral regurgitation combined with mitral stenosis in…
- Trial name
- APOLLO-EU (NCT05496998)
- Testing
- Medtronic Intrepid™ TMVR TF System
- Where
- 37 sites in Denmark, France and 6 more
- Volunteers
- 400 people
- Sponsor
- Medtronic Cardiovascular
Breast Cancer, Gastric Cancer
Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201
This clinical trial will enroll subjects with HER2+ solid tumors and is conducted in two phases, which are phase 1a and phase 1b.
- Conditions
- Breast Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT06341647
- Testing
- AB-201, Cyclophosphamide, Fludarabine
- Sponsor
- GC Cell Corporation
Gastric Cancer, GastroEsophageal Cancer
Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma
The study is a prospective, single arm, phase II trial aimed to evaluate the efficacy and safety of Tumor Treating Fields (TTFields) concomitant with XELOX for the treatment of unresectable, locally advanced or metastatic…
- Trial name
- NCT04281576
- Testing
- NovoTTF-100L(P), Oxaliplatin, Capecitabine
- Where
- Hong Kong
- Volunteers
- 28 people
- Sponsor
- NovoCure Ltd.
Adenocarcinoma
Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas
Investigate the safety and tolerability of ramucirumab (IMC-1121B) drug product (DP) in combination with paclitaxel.
- Trial name
- NCT01253525
- Testing
- Ramucirumab (IMC-1121B ), Paclitaxel
- Where
- 3 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Eli Lilly and Company
Colorectal Cancer, Gastric Adenocarcinoma
A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
This is a Phase 1, multicenter, open-label study of DISP-10, a combination therapy consisting of DV-10 (adenovirus) and idecabtagene vicleucel (ide-cel, BCMA-directed chimeric antigen receptor [CAR] T), in adult participants with…
- Conditions
- Colorectal Cancer, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Adenocarcinoma
- Trial name
- NCT07544589
- Testing
- DISP-10
- Where
- 7 sites in United States
- Volunteers
- 66 people
- Sponsor
- Dispatch Biotherapeutics
Melanoma, Non-small Cell Lung Cancer
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma
- Trial name
- NCT07115043
- Testing
- AZD6750, rilvegostomig
- Where
- 13 sites in United States, Australia and 2 more
- Volunteers
- 120 people
- Sponsor
- AstraZeneca
Advanced Malignancies, Metastatic Cancer
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or metastatic malignancies.
- Trial name
- NCT03126110
- Testing
- INCAGN01876, Nivolumab, Ipilimumab
- Where
- 38 sites in United States, Australia and 2 more
- Volunteers
- 145 people
- Sponsor
- Incyte Biosciences International Sàrl
Gastric Cancer, Gastroesophageal Junction Cancer
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
This is a Phase 2/3, randomized, open-label study for the treatment of patients with HER2-positive Gastric cancer (GC) or Gastroesophageal Junction (GEJ) cancer conducted in two parts.
- Conditions
- Gastric Cancer, Gastroesophageal Junction Cancer, HER2-positive Gastric Cancer
- Trial name
- MAHOGANY (NCT04082364)
- Testing
- margetuximab, Retifanlimab, Tebotelimab
- Where
- 73 sites in United States, China and 7 more
- Volunteers
- 82 people
- Sponsor
- MacroGenics